Abstract-The blood glucose metabolism of a diabetic is a complex nonlinear process closely linked to a number of internal factors which are not easily accessible to measurements. Based on accessible information -such as continuous glucose monitoring (CGM) measurements and information on the amount of ingested carbohydrates and of delivered insulinthe system appears highly stochastic and the quantity of main interest, the blood glucose concentration, is very difficult to model and to predict. In this paper, we approximate the glucoseinsulin system by a linear model with physiologically derived input signals. Considering the time varying characteristics of this system, a normalized least mean squares (NLMS) algorithm with an optimized variable gain is utilized for the recursive estimation of the model coefficients, and its resulting mean square error (MSE) convergence property is investigated. Our experimental results (15 Type 1 diabetic patients) were analyzed from a modeling theory, and also from a clinical point of view using Continuous Glucose-Error Grid Analysis (CG-EGA).
I. INTRODUCTION
Diabetes Mellitus is a well known illness which disturbs and even disables the physiological regulatory mechanisms in charge of keeping the blood glucose (BG) concentration in a target range, typically between 70 and 140 mg/dl, the so called euglycemia [2] . The action of the illness occurs either by reducing and suppressing the endogenous insulin production, in Type 1 Diabetes Mellitus (T1DM), or altering its effectiveness, in Type 2 Diabetes Mellitus (T2DM). Insulin is the only hormone responsible for lowering the blood glucose concentration by inducing its storage in the liver and muscle cells. Therefore, as a consequence of untreated diabetes, hyperglycemia (BG≥ 140 mg/dl -in the case of hospitalized patients- [2] ) may occur leading to critical long-term effects, like blindness and kidney failure.
The standard treatment in T1DM -the main interest of this paper-consists since 1922 in compensating the lack of endogenous insulin by injecting subcutaneously exogenous insulin a few times a day. The main challenge in diabetes management is to estimate the correct quantity of insulin to be injected to keep BG signal within a target range. Indeed, not injecting enough insulin will lead to hyperglycemia, but injecting too much will lead to hypoglycemia (BG≤ 70 mg/dl) which can cause coma and even death. This suggest that the fear of hypoglycemia may represent a significant deterrent in patient decisions. In this regard, hypoglycemia has been described as the complication that patients fear most and the risk of severe hypoglycemia represent a major limit to diabetes self management [9] .
Against this background a project by the European Union called DIAdvisor TM is trying to develop new methods to provide better advice to the patient on the right quantity of insulin to take. Such a decision must be necessarily based on the estimation of the effect of the next meal intake, which implies the existence of a model of the metabolic behavior.
There exist numerous published models of the glucose metabolism starting from the minimal model of Bergman [4] through the Sorensen's model [23] and other physiological models [7] , [22] , [15] , until the recently published Dalla Man -Cobelli model [20] . The key issue is to tune these models to patient characteristics and his current state using accessible information. To this end, we can either start from a (strongly simplified) physiological model and look for an optimal estimate of the unknown parameters, or look directly for a data based approach. Both paths have been tested being [11] and [21] examples of the first and [12] , [25] of the second approach. In this paper, we follow the latter path, motivated by some generic considerations.
First, we should recall that metabolic systems are strongly time varying and include very important stochastic elements. Also the model inputs are affected by human errors (e.g., the estimated amount of carbohydrates done by the patient). Furthermore, many factors affecting both the release rate of glucose from gut or the glucose consumption are not easily accessible to be measured (and probably not even measurable online). So it is questionable whether a precise model of some aspects of the glucose-insulin interplay would provide a much better prediction of the overall behavior. Actually, it is questionable whether a precise model for a specific patient under specific conditions is possible at all.
Second, reliable glucose prediction models will simplify diabetes management hence by predicting future glucose concentrations, the appropriate insulin amount for keeping euglycemia can be calculated, hypoglycemia/hyperglycemia episodes can be prevented before they occur, and the amplitude of the glucose level variation can be reduced.
Keeping these issues in mind, a question arises naturally: can we design a model in order to produce a better performance in terms of tracking capabilities and sensitivity within "dangerous" regions (hyper-and hypoglycemia) while not paying too much attention to the exact values in the target region?
As this paper aims to show, the answer is yes, and it pays off, at least in terms of short term prediction (e.g. 45-minutes). In order to do that, a nonlinear updating factor is required to give little importance to changes in the euglycemia region while taking strongly in account the hyperglycemia and hypoglycaemia regions. As the paper presents, this is possible by extending available normalized least mean square algorithms (NLMS) as described in [3] , [19] . Luckily, conditions on the nonlinear weighting can be derived to preserve the convergence properties of NLMS.
The paper first describes the mathematical problem, then explains the use of the modified NLMS and the design of physiological inspired variable gain, next provides the convergence analysis. After that, clinical target, setup and protocols used for measurements are presented and last but not least shows using measurements on T1DM patients from the DIAdvisor TM project that the proposed method clearly outperforms other alternatives proposed in the literature. [10] shows Error Matrix of CG-EGA for type 2 diabetes 30-min-ahead prediction while in this work is presented results for 45-min-ahead prediction. In the first case, the erroneous readings in hypoglycemia region is 1.77%, in normoglycemia region 0.63% and hyperglycemia region 1.51%. In contrast, in the presented method, the erroneous readings are 1.11% for hypoglycemia region, 0.18% in normoglycemia region and 2.97% in hyperglycemia region. As it can be seen, the presented method outperform the prediction capabilities in normoglycemia and hypoglycemia region (the most dangerous phase for type 1 diabetes).
II. MATHEMATICAL PROBLEM STATEMENT
Consider a discrete-time multiple-input and single-output Autoregressive eXogenous (ARX) system whose dynamic are given by
(1) where u(t) ∈ R, v(t) ∈ R and y(t) ∈ R; n a , n b and n c are the system orders; and a i for i = 1, · · · n a , b j for j = 1, · · · n b and c l for l = 1, · · · n c are the model parameters. Given input/output data {[u(t), v(t)], y(t)} ∞ t=0 , we identify model orders n a , n b and n c , and model parameters a i , b j and c l in order to minimize the sum of squares of the deviations from the data to the model.
For the sake of simplicity, let us assume that n a , n b and
then for all t > max{n a , b b , n c } the regressor vector ϕ(t) leaves in the hyperplane of R G . Equation (1) can be also rearranged as
To emphasize that the calculations of y(t) from past data indeed depend on the estimated parameters in θ , we call this calculated valueŷ(t) = ϕ T (t)θ (t).
The purpose of the adaptive parameter identification algorithms is to estimate the true but unknown parameter vector θ (t) from the observed input/output data set. Letθ (t) be the estimate of θ (t), the general form of many parameter identification algorithms may be described by the following equation (See [18] for more details.)
where K(t) is the gain matrix. As a consequence of abovementioned updating formula, at time t, before the estimatê θ (t) is available, the model output will bê
Among various types of adaptive algorithms for realtime parameter estimation, the normalized least mean square (NLMS) algorithm [27] is well known and its properties have been subject to extensive investigation [16] . The recursive algorithms for updatingθ (t) based on NLMS design is defined bŷ
The primary design parameter in applying NLMS algorithm to practical problems is the selection of the adaptive gain µ so that the algorithm is not only stable, but achieves a good compromise between fast convergence rate and smooth steady state requirements. We now present the NLMS algorithm with a variable gain. The meaning and the choice of the variable gain µ(t) will be discussed in the next section.
III. COMPUTATIONAL ALGORITHMS
Considering that the main application of this algorithm -in our case -is the glucose-insulin system, it seems relevant to include in some way information based on physiology about risky blood glucose levels for type 1 diabetic patients. In general, the gain in the recursive algorithms is a tuning factor which compensates at each step the new error information in the latest measurement and therefore regulates the algorithm's tracking capability. On the one hand, a large gain makes the NLMS algorithm have a better ability for tracking the variation of θ (t). On the other hand, a small gain makes the algorithm less sensitive but at the same time results in a poor tracking ability for systems with some infrequent abrupt parameter changes.
A way to conjugate the tracking capabilities of the gain and the physiological problem is to introduce a variable gain which changes according to blood glucose value. Therefore, the gain is chosen rather low when the first regressor element ϕ 1 (t), which represents the last BG measurement, is within the range of 70−140 mg/dl, whereas it is chosen high in the hypo-and hyperglycemic range. The reason for this is that in euglycemic ranges fast changes of the dynamics are not so likely and thus the algorithm should accumulate more measurement samples to compute the estimate. On the other hand, if the BG is out these bounds, the algorithm should adapt very fast to the new conditions hence a high gain value is proposed. The blood glucose range (20 − 350 mg/dl) is divided in seven levels according to a clinical description (see [2] , [13] ). Table I gives an overview of the glycemic threshold values based on physiological knowledge of the glucose-insulin system. To obtain a continuous definition of the gain (µ d ), the function (8) was implemented
and the variable gain is bounded below and above for all t > max(n a , n b , n c ), i.e., there exist some constants 0 < µ min ≤ µ max ≤ 1, such that µ min ≤ µ(ϕ 1 (t)) ≤ µ max (9) where the constant values λ n and υ n , for n = 1, 2 are estimated by the following optimization problem (10)
To solve this optimization problem, a sample of N total glycemia observations ϕ 1 (m) = (ϕ 1 (1), . . . , ϕ 1 (N total )) and the correspoding set of N total assigned penalties µ d (m) = (µ(1), . . . , µ(N total )), where N total is the number of blood glucose measurements in the full glycemic range is needed. Figure 1 shows the adaptation factor over the whole range of BG. The maximum (µ max ) and minimum (µ min ) value The k-step-ahead glucose predictionŷ(t | t − k,θ ) is a function of current and past observations [19] . For the ARX model given by Equation (6), it can be easily derived a recursive k-step-ahead prediction error algorithm. The maximum and minimum value of the gain function are determined by solving the following optimization problem
whereθ (t) is the estimated parameter vector which depends on the variable gain and therefore on its maximum and minimum bounds. The first constraint is a quite obvious as we want to optimize the bounds of the variable gain function according to the patient's characteristics. The second constraint is imposed in order to avoid over oscillations in the predicted blood glucose signal and due to the fact that the maximum value of the blood glucose derivative distribution in type 1 diabetic patients is 4 mg/dl. (See [8] and the references given there.)
IV. NLMS WITH VARIABLE GAIN: CONVERGENCE
Before presenting convergence properties of the NLMS algorithm with variable gain, we make two standard assumptions to eliminate some unnecessary complications and without loss of generality.
Assumption 1: There exist some constants 0 < N min < N max < ∞ such that for all t 0 < N min ≤ ϕ(t) 2 ≤ N max . The upper bound on ϕ(t) is guaranteed if the system is stable and the input and noise are bounded. The lower bound merely indicates the fact that if ϕ(t) is zero or very small, no information or little information on the unknown parameter vector can be extracted. Even in the case that some information may be extracted when ϕ(t) is very small but not zero, such information is unreliable because of very low signal-to-noise ratio. Therefore the best choice is to interrupt the estimation process whenever time t becomes too small.
Assumption 2:
The regressor is uniformly persistently exciting, i.e., there exist α 1 > 0, α 2 > 0 and an integer m > 0 such that, for all integers t 0 ≥ 0,
Following [16] , we define ε(t) =θ (t) − θ (t). as the parameter error vector. Let us also define the error covariance matrix as
Substituting ε(t) and (7) into (12) we obtain
where
The convergence analysis ofθ (t) to θ (t) is based on the error covariance matrix. To show convergence, expression (15) should be stable
Matrix (15) can be rewritten as
where I is the identity matrix and A(t) denotes a discretetime, time varying matrix defined for t ∈ [0, · · · , ∞[.
Notice that the time varying nature of µ(ϕ 1 (t)) does not produce a problem. To check this, consider that a time varying system is stable if the norm of the transfer matrix A(t) is always bounded by 1, which can be checked as λ max (A(t)) < 1. Recall also that [5] ,
Equation (15) shows the strong dependency with the designed variable gain µ(ϕ 1 (t)). Considering Equation (15)and the statements given above, the following expression holds
Taking into account Assumptions 1 and 2, the terms ϕ(t) and ϕ(t)ϕ T (t) are bounded by [N min N max ] and [α 1 I α 2 I] respectively, this ensures in both cases positive characteristic. In order to check this inequality (18) , it is convenient find conditions for the variable gain µ(t) in the part II of this expression
Replacing expectations with sample means (i.e., E{ f (t)} could be approximated by 1
Considering that I G , Q ∈ R G [5] , [14] , then
Let assumptions 1 and 2 hold. Then, considering the maximum and minimum values for each component in inequality (21), we define bounds for the variable gain µ(ϕ 1 (t)) as
V. EXPERIMENTAL RESULTS
A. Experimental Setup
In the framework of Diadvisor TM European Project, acquisition of clinical diabetes data was accomplished in a series of experimental sessions. All datasets used here were collected during a 76 hour-period in the Centre d'Investigation Clinique du CHU du Montpellier under disturbance-free conditions. The study population consisted of type 1 diabetes individuals (sample size n = 15, 44.33 ± 15.87 years old, body mass index [BMI] = 24.23 ± 3.42 kg/m 2 ) treated with multiple-dose insulin injection therapy. Subjects were hospitalized and prescribed three standard meals for each day. During the whole trial, the patient decided their needs of insulin according to the current BG value and the full dose was delivered before each meal intake, except for lunch on day 2 where the insulin was injected 1 hour after starting eating. A subject's glucose concentration was monitored using Abbott Free Style Navigator TM as CGM system which provides interstitial glucose readings every 10 − min.
Blood samples were collected by the lab to measure blood glucose. Moreover, subjects fill their own logbook to record details about their diabetes management like time and amount of administrated insulin doses, time and estimated carbohydrate content of meal intake. Other factors that can greatly affect glucose concentrations such as exercise or stress were not considered. It is worth mentioning that calibrations against capillary blood glucose values are completed ensuring high quality data.
B. Input Modeling
Plasma insulin concentrations and carbohydrate rate of appearance give important information to the predictor model; however, a usable predictor in daily life relies only on easily available measurements. For this reason, two physiological models were exploited. 1) Meal model: [20] This model is used to generate the rate of appearance of glucose in the intestine following an oral carbohydrate intake. The model was developed with physiological insight of the human gastrointestinal tract.
2) Plasma Rapid Insulin model: The present paper uses a variation of a model described by Verdonk [26] to generate the rate of appearance of insulin in the blood.
C. Optimal bounds of variable gain
The optimal scaling of bounds is calculated by Equation (11) for all 15 patients using the data collected during the first day of the trial. Figure 2 shows the mean and standard deviation for the calculated lower and upper bounds of variable gain and their evolution over k-steps ahead predicted blood glucose. 
D. Prediction model accuracy: From modeler's point of view
The FIT -value defined in [18] and described by (23) is used to assess the performance of prediction models.
where y is the vector of measured glucose values,ŷ is the vector of corresponding glucose predictions, y is the mean value of the y and the indicated norms are Euclidean. Figure 3 displays the evolution of the FIT value over increasing prediction horizon for the whole patient population. Despite the different characteristics of the patients, predictions up to 60-minutes were done with satisfying performance for all of them. A graphical representation of the model output compared with the measurement data for the second and third in-hospital-day (validation sets) for two representative patients 102 and 115 is shown in Figure 4 .
E. Prediction model accuracy: From clinician's point of view
Another way to assess the performance of these prediction models for BG especially is the continuous glucose -error grid analysis (CG-EGA) [6] . Originally designed to evaluate the clinical accuracy of continuous BG sensors in both point and rate of change accuracy, this technique was recently also used for BG predictor evaluation [24] . Predicted glucose values are considered clinically accurate, if they fall into zones A P or B P and A R or B R of the Point-and Rate-EGA respectivelly. However, the areas C P , D P , or E P and C R , D R , or E R of the Point-EGA and Rate-EGA respectivelly lead to negative clinical consequences. Clinically significant errors are defined by a high risk of a dangerous clinical action due to an erroneous prediction.
In order to analize the accuracy of this approach, fifteen predicted profiles were merged to generate a single "global" signal (which resulted consisting of 43200 samples). P-EGA scatter plot clearly shows that nearly all the predicted-measured glucose data pairs fall in the A P zone for the proposed least mean square method with adaptive gain, thus confirming that it provides an accurate proximity between recorded and predicted signals. Very few pairs of points fall in the B P zone for this model. Less than 50 pairs of points fall in the failure to detect D P zone. None fall in the overcorrection C P zone and in the erroneous reading E P zone. R-EGA scatter plot shows that the majority of the predictedmeasured glucose pairs fall in the A R and B R zones for the proposed approach. This confirms the good clinical agreement between measured and predicted glucose levels for 45 minutes of prediction. A few pairs of points fall in the C R zone. This means that the predicted glucose profile would only very rarely lead to overtreatment. Finally, only few pairs of points fall within D R and E R zones. The CG-EGA combines results obtained from the R-EGA and P-EGA to an error-grid matrix [17] . Table II presents the CG-EGA error-grid matrix as defined in [17] . According to Table II , the percentage of clinically accurate predictions or predictions resulting in benign errors in the proposed least mean square method with adaptive gain are 97.35% at hypoglycemia (96.24% accurate + 1.11% benign), 99.8% at euglycemia (99.6% accurate + 0.22% benign) and 98.55% at hyperglycemia (97.47% accurate + 1.08% benign), thus confirming that the performance of the proposed normalized least mean square method with variable gain is accurate in both normal and critical glucose ranges.
VI. CONCLUSION
We applied an online identification method to data from various type 1 diabetic patients. These data sets were quite different in terms of patient anthropological characteristics (e.g bodyweight, sex, BMI, age), and characteristics related to diabetes (e.g. HbA1c, disease duration, insulin delivery). By establishing a physiologically inspired variable gain instead of a constant one, the prediction performance could be improved. As a part of the DIAdvisor TM project, the proposed algorithm will be tested real time on 30 patients in the following months.
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